Notes to the Condensed Consolidated Interim Financial Statements of the Bayer Group as of March 31, 2016

Key Data by Segment

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

Q1 2015

Q1 2016

 

Q1 2015

Q1 2016

 

Q1 2015

Q1 2016

 

Q1 2015

Q1 2016

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2015 figures restated

1

Full-time equivalents

Net sales (external)

 

3,562

3,889

 

1,556

1,520

 

3,092

3,023

 

386

408

Change

 

+14.3%

+9.2%

 

+68.6%

−2.3%

 

+6.6%

−2.2%

 

+17.0%

+5.7%

Currency-adjusted change

 

+6.2%

+12.2%

 

+62.8%

+2.2%

 

+1.5%

+1.3%

 

+6.1%

+8.8%

Intersegment sales

 

10

7

 

1

1

 

10

9

 

1

1

Net sales (total)

 

3,572

3,896

 

1,557

1,521

 

3,102

3,032

 

387

409

EBIT

 

747

698

 

174

243

 

874

970

 

65

114

EBIT before special items

 

771

929

 

263

275

 

921

973

 

97

115

EBITDA before special items

 

1,085

1,261

 

369

383

 

1,040

1,106

 

102

122

Gross cash flow

 

754

961

 

227

285

 

705

778

 

72

86

Net cash flow

 

812

734

 

285

197

 

(823)

(715)

 

120

(20)

Depreciation, amortization and impairments

 

314

563

 

106

121

 

124

133

 

27

7

Number of employees (as of March 31)1

 

40,739

40,315

 

14,591

13,297

 

23,662

23,481

 

3,786

3,853

 

 

Reconciliation

 

 

 

 

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Life Sciences

 

Covestro

 

Group

 

 

Q1 2015

Q1 2016

 

Q1 2015

Q1 2016

 

Q1 2015

Q1 2016

 

Q1 2015

Q1 2016

 

Q1 2015

Q1 2016

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2015 figures restated

1

Full-time equivalents

Net sales (external)

 

268

250

 

1

1

 

8,865

9,091

 

3,014

2,850

 

11,879

11,941

Change

 

−3.9%

−6.7%

 

 

+17.4%

+2.5%

 

+7.5%

−5.4%

 

+14.8%

+0.5%

Currency-adjusted change

 

−5.0%

−6.3%

 

 

+10.9%

+5.9%

 

−2.1%

−4.7%

 

+7.4%

+3.2%

Intersegment sales

 

537

425

 

(572)

(464)

 

 

13

21

 

Net sales (total)

 

805

675

 

(571)

(463)

 

 

3,027

2,871

 

11,879

11,941

EBIT

 

19

3

 

(154)

(29)

 

1,725

1,999

 

219

336

 

1,944

2,335

EBIT before special items

 

25

6

 

(150)

(27)

 

1,927

2,271

 

261

336

 

2,188

2,607

EBITDA before special items

 

70

53

 

(149)

(25)

 

2,517

2,900

 

424

504

 

2,941

3,404

Gross cash flow

 

49

79

 

(108)

(20)

 

1,699

2,169

 

312

407

 

2,011

2,576

Net cash flow

 

(28)

(3)

 

148

141

 

514

334

 

163

169

 

677

503

Depreciation, amortization and impairments

 

45

47

 

1

2

 

617

873

 

184

168

 

801

1,041

Number of employees (as of March 31)1

 

19,876

19,067

 

739

729

 

103,393

100,742

 

14,594

15,740

 

117,987

116,482